Chesterford Research Park has recently announced that Microbiotica, a leading player in microbiome biology, has chosen to relocate to the Park in order to accommodate the company’s immediate and longer-term growth requirements.
Microbiotica joins Lonza Pharma & Biotech as a company that has recently announced they will be relocating their offices from Cambridge to Chesterford Research Park, Essex, in 2020.
Following a period of rapid progress, we require a new facility to support our current growth trajectory and to allow us to consolidate our whole team in one building. Chesterford Research Park has provided us with a solution for our immediate short-term expansion, which was important before our permanent facility, tailored to suit our future needs, is ready in Summer 2020. We very much appreciate the flexibility that Chesterford Research Park has shown us.
Co-founder and CEO
Microbiotica and investment in life sciences
Microbiotica was established in December 2016 as a spin out of the Wellcome Sanger Institute to develop and commercialise the ground-breaking research conducted into the role of the human gut microbiome in health and disease, and its application to medicine. Cambridge Innovation Capital PLC & IP Group PLC co-led an £8m funding investment when Microbiotica was formed.
Microbiotica has a unique capability to culture and genomically characterise the entirety of the bacteria in the human gut for the first time. It has the world’s largest microbiome genome database and culture collection, a suite of translational in vitro and animal models, and state of the art bioinformatics and AI.
As such, the company is well positioned to become a world leader in microbiome-based therapeutics and biomarkers, Microbiotica has a focus on IBD and Immuno-Oncology, and a program in C. difficile which is spearheading innovation in development of live bacterial products.
According to a life science report by BioCity, the amount of investment in the life sciences sector has taken off in the last five years, with investment increasing four-fold to approximately £2.8bn. The report states that ‘over the past five years the life sciences industry has experienced a period of growth not previously seen this century’.
Joining the Essex life sciences community
Under the first phase of the relocation, Microbiotica is taking two suites within Chesterford Research Park’s Science Village, a short-term solution to facilitate current growth requirements. Until June 2020, Microbiotica will retain its current premises at the Wellcome Genome Campus, at which point the whole organisation will move into its own purpose-designed facilities in the Newnham Building, which is currently undergoing reconfiguration and refurbishment.
Situated in a prominent position on the Park, within close reach of the well-appointed central Nucleus facilities, the Newnham Building will provide a newly-constructed double height glazed reception to the western entrance as well as a new entrance to the eastern end of the building. The flexibility of the building has enabled it to be divided into individual suites, which can cater for a range of differing scientific activities.
There has been a high level of interest in the Newnham Building. Confirmation of Microbiotica’s pre-let, coupled with the recent announcement that existing Park occupier, Isomerase is also committed to a suite, leaves just one 11,518 sq ft (1,070 sq m) suite. This is currently being marketed by Savills and Cheffins.
About Chesterford Research Park
Chesterford Research Park has proven an ideal environment for life science companies to grow and prosper. Leading bioscience names that have located at Chesterford include AstraZeneca, Arecor, Charles River Laboratories, DRW, Domainex and Isogenica.
The attractive 250-acre, low-density development is located close to Cambridge and the M11 with London just one hour away by train from nearby Audley End station, ensuring occupiers and visitors enjoy convenient and easy access. London Stansted Airport is just 20 minutes’ drive away.
To date, more than 350,000 sq ft of laboratory R&D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately 1 million sq ft.